Assembly Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Assembly Biosciences is de winst gegroeid met een gemiddeld jaarlijks percentage van 6.6%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.1%. De inkomsten zijn gedaald met een gemiddelde van 34.3% per jaar.

Belangrijke informatie

6.6%

Groei van de winst

21.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-34.3%
Rendement op eigen vermogen	-156.9%
Nettomarge	-144.1%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers

Nov 13

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Oct 05

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Jul 20

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jun 08

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jan 11

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Sep 03

Assembly Biosciences announces resignation of CFO

Jun 02

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Mar 24

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

Feb 05

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Dec 14

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Nov 16

Assembly Biosciences EPS beats by $0.69, beats on revenue

Nov 05

Opbrengsten en kosten

Hoe Assembly Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:ASMB Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	28	-41	22	0
30 Jun 24	21	-46	22	0
31 Mar 24	13	-51	23	0
31 Dec 23	7	-61	23	0
30 Sep 23	0	-73	21	0
30 Jun 23	0	-81	22	0
31 Mar 23	0	-89	23	0
31 Dec 22	0	-93	24	0
30 Sep 22	0	-131	24	0
30 Jun 22	6	-127	25	0
31 Mar 22	6	-126	26	0
31 Dec 21	6	-130	29	0
30 Sep 21	7	-109	29	0
30 Jun 21	36	-94	34	0
31 Mar 21	75	-63	37	0
31 Dec 20	79	-62	37	0
30 Sep 20	83	-50	39	0
30 Jun 20	52	-71	36	0
31 Mar 20	16	-97	34	0
31 Dec 19	16	-98	35	0
30 Sep 19	15	-97	34	0
30 Jun 19	15	-93	34	0
31 Mar 19	15	-102	34	0
31 Dec 18	15	-91	30	0
30 Sep 18	14	-68	27	0
30 Jun 18	13	-58	23	0
31 Mar 18	12	-45	19	0
31 Dec 17	9	-43	17	0
30 Sep 17	6	-51	15	0
30 Jun 17	3	-51	14	0
31 Mar 17	1	-47	13	0
31 Dec 16	0	-44	12	0
30 Sep 16	0	-40	12	5
30 Jun 16	0	-36	12	10
31 Mar 16	0	-32	11	15
31 Dec 15	0	-28	11	0
30 Sep 15	0	-27	12	16
30 Jun 15	0	-31	17	15
31 Mar 15	0	-27	15	12
31 Dec 14	0	-24	13	11
30 Sep 14	0	-24	11	13
30 Jun 14	0	-17	5	13
31 Mar 14	0	-20	5	15

Kwaliteitswinsten: ASMB is momenteel verliesgevend.

Groeiende winstmarge: ASMB is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ASMB is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 6.6% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ASMB over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ASMB is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: ASMB heeft een negatief Return on Equity ( -156.92% ), omdat het momenteel verliesgevend is.

Assembly Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.094 loss in 3Q 2020)

Full year 2020 earnings released: US$1.75 loss per share (vs US$3.72 loss in FY 2019)

Third quarter 2020 earnings released: US$0.094 loss per share

First half earnings released

Recent updates

New minor risk - Market cap size

Consensus revenue estimates decrease by 11%, EPS upgraded

Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers

Assembly Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

New minor risk - Share price stability

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors At International Herpesvirus Workshop

Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.

Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024

Assembly Biosciences, Inc., Annual General Meeting, May 29, 2024

Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board

New major risk - Revenue and earnings growth

Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer

New major risk - Share price stability

Assembly Biosciences Receives Non-Compliance Notice from Nasdaq

Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

New major risk - Revenue and earnings growth

Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely

New minor risk - Insider selling

Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?

Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

Assembly Biosciences, Inc. Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

High number of new directors

Assembly Biosciences, Inc. Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences, Inc. Presents New Data at AASLD Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Price target decreased to US$7.38

High number of new directors

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences, Inc. Announces Management Appointments

Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end

Assembly Biosciences, Inc. Announces Executive Changes

Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce

Assembly Biosciences, Inc. to Introduce New Small Molecule Liver-Focused Interferon-a Receptor Agonist Research Program

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences Inc. Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

High number of new directors

Assembly Biosciences, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Consensus forecasts updated

Price target increased to US$10.90

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.094 loss in 3Q 2020)

Price target decreased to US$9.71

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from Russell Microcap Growth Index

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs At the International Liver Congress™ EASL 2021

CFO & Principal Accounting Officer Thomas Russo has left the company

Assembly Biosciences announces resignation of CFO

Consensus revenue estimates fall to US$6.63m

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Analysts update estimates

Price target lowered to US$11.60

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

Full year 2020 earnings released: US$1.75 loss per share (vs US$3.72 loss in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$6.45

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Assembly Biosciences, Inc. Announces Board Changes, Effective December 31, 2020

Assembly Biosciences, Inc. Appoints Nicole S. White as Senior Vice President of Pharmaceutical Development and Manufacturing

Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators

Analysts increase revenue estimates to US$81.8m

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.094 loss per share

Price target raised to US$49.25

Assembly Bio Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Assembly Biosciences EPS beats by $0.69, beats on revenue

Assembly Biosciences, Inc. Announces HBV Core Inhibitor Research and Development Program

New 90-day low: US$14.87